Table 2.
Comparison of out-of-hospital cardiac arrest (OHCA) victims who received an Angio-Seal™ after coronary angiography and those who did not receive an Angio-Seal™ with special attention to additional treatment with mild therapeutic hypothermia
| Patients treated with MTH | Patients not treated with MTH | |||||
|---|---|---|---|---|---|---|
| Angio-Seal™ n = 16 |
No Angio-Seal™ n = 32 |
p | Angio-Seal™ n = 10 |
No Angio-Seal™ n = 18 |
p | |
| Male gender | 8 (50.0%) | 21 (65.6%) | 0.30 | 5 (50.0%) | 12 (66.7%) | 0.39 |
| Age (years) [range] |
66.0 ± 14.6 [37-88] |
60.4 ± 13.0 [34-87] |
0.19 | 66.8 ± 15.4 [47-88] |
67.9 ± 8.7 [53-85] |
0.81 |
| Witnessed cardiac arrest | 13 (81.3%) | 25 (78.1%) | 0.13 | 7 (70.0%) | 15 (83.3%) | 0.14 |
| Lay resuscitation | 6 (37.5%) | 16 (50.0%) | 0.41 | 8 (80.0%) | 13 (72.2%) | 0.73 |
| Initial shockable rhythm | 8 (50.0%) | 22 (68.8%) | 0.21 | 6 (60.0%) | 8 (44.4%) | 0.52 |
| Myocardial infarction | 5 (31.3%) | 20 (62.5%) | 0.03 | 5 (50.0%) | 8 (44.4%) | 0.79 |
| ST elevation myocardial infarction | 5 (31.3%) | 14 (43.8%) | 3 (30.0%) | 5 (27.8%) | ||
| (STEMI) | 0 (0.0%) | 6 (18.8%) | 2 (20.0%) | 3 (16.7%) | ||
| Non-ST elevation myocardial infarction (NSTEMI) | ||||||
| Coronary artery disease | 11 (68.8%) | 29 (90.6%) | 0.06 | 8 (80.0%) | 15 (83.3%) | 0.83 |
| One vessel disease | 2 (12.5%) | 5 (15.6%) | 0 (0.0%) | 6 (33.3%) | ||
| Two vessel disease | 5 (31.3%) | 7 (21.9%) | 3 (30.0%) | 2 (11.1%) | ||
| Three vessel disease | 4 (25.0%) | 17 (53.1%) | 5 (50.0%) | 7 (38.9%) | ||
| Percutaneous coronary intervention (PCI) | 8 (50.0%) | 27 (84.4%) | 0.01 | 7 (70.0%) | 11 (61.1%) | 0.64 |
| Left anterior descendens (LAD) | 4 (25.0%) | 12 (37.5%) | 2 (20.0%) | 3 (16.7%) | ||
| Ramus circumflexus (RCX) | 0 (0.0%) | 4 (12.5%) | 1 (10.0%) | 2 (11.1%) | ||
| Right coronary artery (RCA) | 3 (18.8%) | 5 (15.6%) | 1 (10.0%) | 5 (27.8%) | ||
| Multi vessel disease (MV) | 1 (6.3%) | 5 (15.6%) | 3 (30.0%) | 1 (5.6%) | ||
| Coronary artery bypass graft (CABG) | 0 (0.0%) | 1 (3,1%) | 0 (0.0%) | 0 (0.0%) | ||
| Use of Eptifibatide (Integrilin™) | 1 (6.3%) | 11 (34.4%) | 0.03 | 1 (10.0%) | 4 (22.2%) | 0.42 |
| Duration of coronary angiography (min) [range] |
34.4 ± 21.6 [8-93] |
55.3 ± 27.0 [15-132] |
0.01 | 58.5 ± 54.4 [7-186] |
46.8 ± 20.2 [16-76] |
0.42 |
| Vascular complication | 3 (18.8%) | 3 (9.4%) | 0.36 | 0 (0.0%) | 0 (0.0%) | n.a. |
| Hb relevant bleeding | 3 (18.8%) | 2 (6.3%) | 0.18 | - | - | |
| conservative therapy | 1 (6.3%) | 0 (0.0%) | - | - | ||
| transfusion | 1 (6.3%) | 2 (6.3%) | - | - | ||
| operation | 1 (6.3%) | 0 (0.0%) | - | - | ||
| Arterial occlusion | 0 (0.0%) | 1 (3.1%) | 0.48 | - | - | |
| operation | - | 1 (3.1%) | - | - | ||
| Survival until hospital discharge | 8 (50.0%) | 19 (59.4%) | 0.54 | 6 (60.0%) | 8 (44.4%) | 0.43 |
n.a.: not available